HRMY · Harmony Biosciences Holdings, Inc.
AI read · Good for HRMY
The AI's read
Harmony delivered record Q2 revenue, WAKIX sales up ~30%, and beat EPS estimates. They also released Phase 1 SAD data for BP-205 showing clean PK and tolerability. The market already bid the stock up roughly 8.9% on the print. RSI is 47.86, so price action looks like a fresh reaction rather than an overbought melt-up. We lean bullish because hard commercial growth plus early pipeline proof expands the company's runway. Conviction is restrained since guidance was reiterated and the beat was modest versus consensus.